Please ensure Javascript is enabled for purposes of website accessibility
Turnaround Letter
Out-of-Favor Stocks with Real Value

April 21, 2025

Sell Teladoc Health (TDOC)

Sell Teladoc Health (TDOC)

Today I’m recommending that we sell the remaining three-quarters of our position in Teladoc Health (TDOC).

After taking a one-quarter profit in the stock in February following the rally, the stock has drastically underperformed since then. The weakness hasn’t been without reason, as the company has struggled to successfully implement its strategic plan and leverage its platform to offer more personalized care. Instead, what we’re seeing is lower utilization rates and continued losses, with the new management having difficulty executing the turnaround and with prospects looking increasingly bleak. Additionally, there’s a big question mark surrounding next week’s (April 30) Q1 earnings report, and I’m not willing to endure additional losses. SELL


Copyright © 2025. All rights reserved. Copying or electronic transmission of this information without permission is a violation of copyright law. For the protection of our subscribers, copyright violations will result in immediate termination of all subscriptions without refund. Disclosures: Cabot Wealth Network exists to serve you, our readers. We derive 100% of our revenue, or close to it, from selling subscriptions to our publications. Neither Cabot Wealth Network nor our employees are compensated in any way by the companies whose stocks we recommend or providers of associated financial services. Employees of Cabot Wealth Network may own some of the stocks recommended by our advisory services. Disclaimer: Sources of information are believed to be reliable but they are not guaranteed to be complete or error-free. Recommendations, opinions or suggestions are given with the understanding that subscribers acting on information assume all risks involved. Buy/Sell Recommendations: are made in regular issues, updates, or alerts by email and on the private subscriber website. Subscribers agree to adhere to all terms and conditions which can be found on CabotWealth.com and are subject to change. Violations will result in termination of all subscriptions without refund in addition to any civil and criminal penalties available under the law.

Clif Droke is the Chief Analyst of Cabot Turnaround Letter. For over 20 years, he has worked as a writer, analyst and editor of several market-oriented advisory services and has written several books on technical trading in the stock market, including “Channel Buster: How to Trade the Most Profitable Chart Pattern” and “The Stock Market Cycles” as well as “Turnaround Trading & Investing: Tactics and Techniques for Spotting Winning Turnaround Stocks.”